PT  - JOURNAL ARTICLE
AU  - Nichols, Emma Hitt
ED  - Piccart-Gebhart, Martine J.
TI  - HERA TRIAL: 2 Years versus 1 Year of Trastuzumab after Adjuvant Chemotherapy in Women with HER2-Positive Early Breast Cancer at 8 Years of Median Follow-Up
DP  - 2013 Mar 01
TA  - MD Conference Express
PG  - 9--10
VI  - 12
IP  - 20
4099  - http://mdc.sagepub.com/content/12/20/9.2.short
4100  - http://mdc.sagepub.com/content/12/20/9.2.full
AB  - In 2005, data from 3 large randomized trials demonstrated that 1 year of trastuzumab treatment provided a statistically significant disease-free survival benefit compared with no trastuzumab in patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer [Piccart-Gebhart MJ et al. N Engl J Med 2005]. One of these studies, the Trastuzumab in Treating Women with Primary Breast Cancer [HERceptin Adjuvant (HERA); NCT00045032] trial, continued trastuzumab therapy to assess whether 2 years of treatment was superior to 1 year. This article provides an update of the HERA trial after 8 years of median follow-up.